iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer

Yiming Ma, Ting Xiao, Quan Xu, Xinxin Shao, Hongying Wang

PDF(219 KB)
PDF(219 KB)
Front. Med. ›› 2016, Vol. 10 ›› Issue (3) : 278-285. DOI: 10.1007/s11684-016-0453-z
RESEARCH ARTICLE

iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer

Author information +
History +

Abstract

Colorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. We aimed to find novel molecules as potential biomarkers for the early diagnosis of CRC. A serum-free conditioned medium was successfully collected from three pairs of CRC tissue and adjacent normal tissue. iTRAQ-based quantitative proteomic analysis was applied to compare the differences in secretome between primary CRC mucosa and adjacent normal mucosa. A total of 145 kinds of proteins were identified. Of these proteins, 29 were significantly different between CRC and normal tissue. Tropomyosin 2 β (TPM2) exhibited the most significant differences; as such, this protein was selected for further validation. Quantitative real-time PCR indicated that the mRNA expression of TPM2 significantly decreased in the CRC tissue compared with the paired adjacent normal tissue. Immunohistochemical analysis also confirmed that TPM2 was barely detected at protein levels in the CRC tissue. In summary, this study revealed potential molecules for future biomarker applications and provided an efficient approach for the differential analysis of cancer-associated secretome. TPM2 may be valuable for the early diagnosis of CRC.

Keywords

iTRAQ / secretome / colorectal cancer / TPM2

Cite this article

Download citation ▾
Yiming Ma, Ting Xiao, Quan Xu, Xinxin Shao, Hongying Wang. iTRAQ-based quantitative analysis of cancer-derived secretory proteome reveals TPM2 as a potential diagnostic biomarker of colorectal cancer. Front. Med., 2016, 10(3): 278‒285 https://doi.org/10.1007/s11684-016-0453-z

References

[1]
Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin 2015; 65(2): 87–108
CrossRef Pubmed Google scholar
[2]
Chen W, Zheng R, Zeng H, Zhang S, He J. Annual report on status of cancer in China, 2011. Chin J Cancer Res 2015; 27(1): 2–12
CrossRef Google scholar
[3]
Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2008: a review of current American Cancer Society guidelines and cancer screening issues. CA Cancer J Clin 2008; 58(3): 161–179
CrossRef Pubmed Google scholar
[4]
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 69–90
CrossRef Pubmed Google scholar
[5]
Jiang X, Wang Y, Wang H, Geng M, Liu YL. Typical symptoms of colorectal cancer and its influence in timely diagnosis. Natl J Med China (Zhonghua Yi Xue Za Zhi) 2013; 93(4): 275–279 (in Chinese)
Pubmed
[6]
He J, Efron JE. Screening for colorectal cancer. Adv Surg 2011; 45(1): 31–44
CrossRef Pubmed Google scholar
[7]
Moawad FJ, Maydonovitch CL, Cullen PA, Barlow DS, Jenson DW, Cash BD. CT colonography may improve colorectal cancer screening compliance. AJR Am J Roentgenol 2010; 195(5): 1118–1123
CrossRef Pubmed Google scholar
[8]
Parra-Blanco A, Gimeno-García AZ, Quintero E, Nicolás D, Moreno SG, Jiménez A, Hernández-Guerra M, Carrillo-Palau M, Eishi Y, López-Bastida J. Diagnostic accuracy of immunochemical versus guaiac faecal occult blood tests for colorectal cancer screening. J Gastroenterol 2010; 45(7): 703–712
CrossRef Pubmed Google scholar
[9]
Bhatti I, Patel M, Dennison AR, Thomas MW, Garcea G. Utility of postoperative CEA for surveillance of recurrence after resection of primary colorectal cancer. Int J Surg 2015; 16(Pt A):123–128
[10]
Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol 2009; 18(1): 15–24
CrossRef Pubmed Google scholar
[11]
Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clin Chem 2001; 47(4): 624–630
Pubmed
[12]
Veenstra TD, Conrads TP, Hood BL, Avellino AM, Ellenbogen RG, Morrison RS. Biomarkers: mining the biofluid proteome. Mol Cell Proteomics 2005; 4(4): 409–418
CrossRef Pubmed Google scholar
[13]
Schmidt A, Aebersold R. High-accuracy proteome maps of human body fluids. Genome Biol 2006; 7(11): 242
CrossRef Pubmed Google scholar
[14]
Liu Z, Zhang Y, Niu Y, Li K, Liu X, Chen H, Gao C. A systematic review and meta-analysis of diagnostic and prognostic serum biomarkers of colorectal cancer. PLoS ONE 2014; 9(8): e103910
CrossRef Pubmed Google scholar
[15]
Yao L, Lao W, Zhang Y, Tang X, Hu X, He C, Hu X, Xu LX. Identification of EFEMP2 as a serum biomarker for the early detection of colorectal cancer with lectin affinity capture assisted secretome analysis of cultured fresh tissues. J Proteome Res 2012; 11(6): 3281–3294
CrossRef Pubmed Google scholar
[16]
de Wit M, Kant H, Piersma SR, Pham TV, Mongera S, van Berkel MP, Boven E, Pontén F, Meijer GA, Jimenez CR, Fijneman RJ. Colorectal cancer candidate biomarkers identified by tissue secretome proteome profiling. J Proteomics 2014; 99: 26–39PMID:24418523
CrossRef Google scholar
[17]
Tang HY, Ali-Khan N, Echan LA, Levenkova N, Rux JJ, Speicher DW. A novel four-dimensional strategy combining protein and peptide separation methods enables detection of low-abundance proteins in human plasma and serum proteomes. Proteomics 2005; 5(13): 3329–3342
CrossRef Pubmed Google scholar
[18]
Rai AJ, Gelfand CA, Haywood BC, Warunek DJ, Yi J, Schuchard MD, Mehigh RJ, Cockrill SL, Scott GB, Tammen H, Schulz-Knappe P, Speicher DW, Vitzthum F, Haab BB, Siest G, Chan DW. HUPO Plasma Proteome Project specimen collection and handling: towards the standardization of parameters for plasma proteome samples. Proteomics 2005; 5(13): 3262–3277
CrossRef Pubmed Google scholar
[19]
Fang X, Zhang WW. Affinity separation and enrichment methods in proteomic analysis. J Proteomics 2008; 71(3): 284–303
CrossRef Pubmed Google scholar
[20]
Xiao T, Ying W, Li L, Hu Z, Ma Y, Jiao L, Ma J, Cai Y, Lin D, Guo S, Han N, Di X, Li M, Zhang D, Su K, Yuan J, Zheng H, Gao M, He J, Shi S, Li W, Xu N, Zhang H, Liu Y, Zhang K, Gao Y, Qian X, Cheng S. An approach to studying lung cancer-related proteins in human blood. Mol Cell Proteomics 2005; 4(10): 1480–1486
CrossRef Pubmed Google scholar
[21]
Lou X, Xiao T, Zhao K, Wang H, Zheng H, Lin D, Lu Y, Gao Y, Cheng S, Liu S, Xu N. Cathepsin D is secreted from M-BE cells: its potential role as a biomarker of lung cancer. J Proteome Res 2007; 6(3): 1083–1092
CrossRef Pubmed Google scholar
[22]
Li M, Xiao T, Zhang Y, Feng L, Lin D, Liu Y, Mao Y, Guo S, Han N, Di X, Zhang K, Cheng S, Gao Y. Prognostic significance of matrix metalloproteinase-1 levels in peripheral plasma and tumour tissues of lung cancer patients. Lung Cancer 2010; 69(3): 341–347
CrossRef Pubmed Google scholar
[23]
Polisetty RV, Gautam P, Sharma R, Harsha HC, Nair SC, Gupta MK, Uppin MS, Challa S, Puligopu AK, Ankathi P, Purohit AK, Chandak GR, Pandey A, Sirdeshmukh R. LC-MS/MS analysis of differentially expressed glioblastoma membrane proteome reveals altered calcium signaling and other protein groups of regulatory functions. Mol Cell Proteomics 2012; 11(6): 013565
CrossRef Pubmed Google scholar
[24]
Albrethsen J, Bøgebo R, Gammeltoft S, Olsen J, Winther B, Raskov H. Upregulated expression of human neutrophil peptides 1, 2 and 3 (HNP 1-3) in colon cancer serum and tumours: a biomarker study. BMC Cancer 2005; 5(1): 8
CrossRef Pubmed Google scholar
[25]
Ward DG, Suggett N, Cheng Y, Wei W, Johnson H, Billingham LJ, Ismail T, Wakelam MJ, Johnson PJ, Martin A. Identification of serum biomarkers for colon cancer by proteomic analysis. Br J Cancer 2006; 94(12): 1898–1905
CrossRef Pubmed Google scholar
[26]
de Noo ME, Mertens BJ, Ozalp A, Bladergroen MR, van der Werff MP, van de Velde CJ, Deelder AM, Tollenaar RA. Detection of colorectal cancer using MALDI-TOF serum protein profiling. Eur J Cancer 2006; 42(8): 1068–1076
CrossRef Pubmed Google scholar
[27]
Pavlou MP, Diamandis EP. The cancer cell secretome: a good source for discovering biomarkers? J Proteomics 2010; 73(10): 1896–1906
CrossRef Pubmed Google scholar
[28]
Xue H, Lü B, Zhang J, Wu M, Huang Q, Wu Q, Sheng H, Wu D, Hu J, Lai M. Identification of serum biomarkers for colorectal cancer metastasis using a differential secretome approach. J Proteome Res 2010; 9(1): 545–555
CrossRef Pubmed Google scholar
[29]
Volmer MW, Stühler K, Zapatka M, Schöneck A, Klein-Scory S, Schmiegel W, Meyer HE, Schwarte-Waldhoff I. Differential proteome analysis of conditioned media to detect Smad4 regulated secreted biomarkers in colon cancer. Proteomics 2005; 5(10): 2587–2601
CrossRef Pubmed Google scholar
[30]
Shi HJ, Stubbs R, Hood K. Characterization of de novo synthesized proteins released from human colorectal tumour explants. Electrophoresis 2009; 30(14): 2442–2453
CrossRef Pubmed Google scholar
[31]
Kikuchi Y, Kashima TG, Nishiyama T, Shimazu K, Morishita Y, Shimazaki M, Kii I, Horie H, Nagai H, Kudo A, Fukayama M. Periostin is expressed in pericryptal fibroblasts and cancer-associated fibroblasts in the colon. J Histochem Cytochem 2008; 56(8): 753–764
CrossRef Pubmed Google scholar
[32]
Ben QW, Zhao Z, Ge SF, Zhou J, Yuan F, Yuan YZ. Circulating levels of periostin may help identify patients with more aggressive colorectal cancer. Int J Oncol 2009; 34(3): 821–828
Pubmed
[33]
Bao S, Ouyang G, Bai X, Huang Z, Ma C, Liu M, Shao R, Anderson RM, Rich JN, Wang XF. Periostin potently promotes metastatic growth of colon cancer by augmenting cell survival via the Akt/PKB pathway. Cancer Cell 2004; 5(4): 329–339
CrossRef Pubmed Google scholar
[34]
Zhang J, Wang K, Zhang J, Liu SS, Dai L, Zhang JY. Using proteomic approach to identify tumor-associated proteins as biomarkers in human esophageal squamous cell carcinoma. J Proteome Res 2011; 10(6): 2863–2872
CrossRef Pubmed Google scholar
[35]
Tang HY, Beer LA, Tanyi JL, Zhang R, Liu Q, Speicher DW. Protein isoform-specific validation defines multiple chloride intracellular channel and tropomyosin isoforms as serological biomarkers of ovarian cancer. J Proteomics 2013; 89: 165–178
CrossRef Pubmed Google scholar
[36]
Li DQ, Wang L, Fei F, Hou YF, Luo JM, Zeng R, Wu J, Lu JS, Di GH, Ou ZL, Xia QC, Shen ZZ, Shao ZM. Identification of breast cancer metastasis-associated proteins in an isogenic tumor metastasis model using two-dimensional gel electrophoresis and liquid chromatography-ion trap-mass spectrometry. Proteomics 2006; 6(11): 3352–3368PMID:16637015
CrossRef Google scholar

Acknowledgements

This work was financially supported by National Basic Research Program of China (973 Program, No. 2011CB910700) and National Natural Science Foundation of China (No. 81201966).

Compliance with ethics guidelines

Yiming Ma, Ting Xiao, Quan Xu, Xinxin Shao, and Hongying Wang declare that they have no conflict of interest. All procedures related to human samples were approved by the Review Board of Chinese Academy of Medical Sciences Cancer Institute. Informed consent was obtained from all patients for inclusion in the study.

RIGHTS & PERMISSIONS

2016 Higher Education Press and Springer-Verlag Berlin Heidelberg
AI Summary AI Mindmap
PDF(219 KB)

Accesses

Citations

Detail

Sections
Recommended

/